{{Rsnum
|rsid=533556
|Gene=SIK3
|Chromosome=11
|position=116870856
|Orientation=plus
|GMAF=0.3696
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;C)
|geno3=(C;C)
|Gene_s=SIK3
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;C)
| geno3=(C;C)
| CEU | 7.1 | 45.5 | 47.3
| HCB | 64.7 | 30.1 | 5.1
| JPT | 66.4 | 29.2 | 4.4
| YRI | 89.1 | 9.5 | 1.4
| ASW | 73.7 | 19.3 | 7.0
| CHB | 64.7 | 30.1 | 5.1
| CHD | 69.4 | 27.8 | 2.8
| GIH | 46.5 | 41.6 | 11.9
| LWK | 91.7 | 7.3 | 0.9
| MEX | 29.8 | 56.1 | 14.0
| MKK | 60.9 | 33.3 | 5.8
| TSI | 17.6 | 46.1 | 36.3
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs533556
|Name_s=rs533556 (APOA1) C>A
|Gene_s=KIAA0999
|Feature=
|Evidence=PubMed ID:20195290
|Annotation=Risk or phenotype-associated allele: A Phenotype: This SNP was associated with a greater reduction in total cholesterol after at least 1 week of statin use. This was not replicated in a second cohort. Study size: 546 (original cohort); 100 (replication cohort). Study population/ethnicity: People taking statins; age 55 or older; Rotterdam Study; Netherlands. Significance metric(s): p = 0.05 (original); p = 0.975 (replication) Type of association: PD.
|Drugs=
|Drug Classes=HMG COA REDUCTASE INHIBITORS
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291808
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs533556
|overall_frequency_n=50
|overall_frequency_d=126
|overall_frequency=0.396825
|n_genomes=30
|n_genomes_annotated=0
|n_haplomes=39
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | Illumina Human 1M}}
{{on chip | NatGeo2}}